Disposition, Elimination and Haemodynamic Effects of Gallopamil in Patients with Fatty Liver Disease
- 6 Downloads
Twenty-one hypertensive patients were treated orally with 50mg gallopamil in a sustained-release formulation once daily for 1 week. 11 patients had a normal liver function (antipyrine clearance 41.2 ± 2.8 ml/min; mean ± SD), while 10 patients had fatty liver disease (antipyrine clearance 32.3 ± 1.4 ml/min). Maximum plasma concentrations of gallopamil were 15.2 (7.9 to 29.3) µg/L (geometric mean; 95% confidence interval) in patients with normal and 16.8 (8.7 to 32.5) µg/L in those with impaired hepatic function (p > 0.05). The elimination half-life was 8.8 hours in patients with normal liver function and 9.2 hours in patients with fatty liver disease (median, p > 0.05). No significant differences were found between patients with and without concomitant liver disease with regard to the effects of gallopamil on heart rate, PQ-time and blood pressure. First degree AV-block developed during treatment with gallopamil in one patient with fatty liver disease and in another with normal liver function. The AV-block in the patient with impaired hepatic function was considered to be severe (PQ-time 270ms). In conclusion, kinetic parameters of patients with fatty liver disease did not differ significantly from those of subjects with normal liver function.
KeywordsNifedipine Fatty Liver Disease Antipyrine Drug Invest Nitrendipine
Unable to display preview. Download preview PDF.
- 3.Stieren B, Bühler V, Hege HG, et al. Pharmacokinetics and metabolism of gallopamil. In: Kaltenbach M, Hopf R, editors. Gallopamil, pharmacological and clinical profile of a calcium antagonist. Berlin: Springer, 1984: 88–93Google Scholar
- 4.Eichelbaum M, Mikus G. Pharmacokinetics, bioavailability, cardiovascular and biochemical effects of gallopamil in patients with liver cirrhosis and in healthy subjects without liver disease. Internal Report, Dr M. Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany, 1992: 1–9Google Scholar
- 5.Kaim AAH, Farker K. Pharmacokinetics and pharmacodynamics of gallopamil in patients with liver cirrhosis [abstract no. 36]. Naunyn Schmiedebergs Arch Pharmacol 1992; 345 Suppl.: R9Google Scholar
- 6.Mensink CK, Hempenius J, Wilkens G, et al. Determination of gallopamil and norgallopamil in human plasma by high performance liquid chromatography and fluorescence detection. Description and validation of assay method. Internal Report, Pharma Bio-Reasearch International, Zuidlaren, Netherlands, 1990Google Scholar
- 8.Sachs L. Angewandte Statistik. 7th ed. Berlin: Springer, 1992Google Scholar
- 11.Lasseter KC, Shambleu EC, Murdoch AA, et al. Steady state pharmacokinetics of nitrendipine in hepatic insufficiency. J Cardiovasc Pharmacol 1984; 6 Suppl. 7: 977–81Google Scholar